TROVW Profile
Trovagene, Inc. (TROVW) is a clinical-stage biotechnology company based in San Diego, California. The company is focused on the development of precision cancer medicines that target key signaling pathways involved in the growth and spread of cancer.
As of the close of trading on February 18, 2023, Trovagene's stock was trading at $0.64 per unit. The company has a market capitalization of approximately $18.5 million.
Trovagene's lead product candidate is Onvansertib, a highly selective and potent inhibitor of polo-like kinase 1 (PLK1), which is involved in multiple aspects of cell division and has been identified as a key target in multiple types of cancer. The company is currently conducting clinical trials of Onvansertib in combination with other cancer therapies for the treatment of various types of solid tumors and blood cancers.
Trovagene is also developing a pipeline of preclinical product candidates that target other signaling pathways involved in cancer growth and progression, including the Wnt/beta-catenin pathway and the KRAS oncogene.
In terms of financial performance, Trovagene reported a net loss of $13.3 million for the full year 2021, compared to a net loss of $11.9 million in the previous year. The company has a cash balance of approximately $16 million as of December 31, 2021, which it believes is sufficient to fund its operations through mid-2023.
Overall, Trovagene is a clinical-stage biotechnology company focused on the development of precision cancer medicines. While the company has a promising pipeline of product candidates and is conducting clinical trials of its lead candidate, investors should carefully consider the risks and potential rewards before investing in Trovagene's stock, as the company faces significant challenges in the highly competitive and rapidly evolving field of oncology drug development.
|
